Page last updated: 2024-12-10

chanoclavine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

chanoclavine: RN given refers to (4R-(4alpha,5beta(E)))-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

chanoclavine-I : An organic tricyclic compound that is 1,3,4,5-tetrahydrobenzo[cd]indole which is substituted at position 4 by a methylamino group and at position 5 by a 3-hydroxy-2-methylprop-1-en-1-yl group (the 4R,5R,E diastereoisomer). It is a precursor of the tetracyclic ergolines agroclavine, elymoclavine and lysergic acid amide. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5281381
CHEBI ID3576
MeSH IDM0049821

Synonyms (22)

Synonym
chanoclavine-i
2390-99-0
C09131
32x6f73re2 ,
chanoclavine
unii-32x6f73re2
chanoclavin-i
2-propen-1-ol, 2-methyl-3-(1,3,4,5-tetrahydro-4-(methylamino)benz(cd)indol-5-yl)-, (4r-(4alpha,5beta(e)))-
(2e)-2-methyl-3-[(4r,5r)-4-(methylamino)-1,3,4,5-tetrahydrobenzo[cd]indol-5-yl]prop-2-en-1-ol
CHEBI:3576
2-propen-1-ol, 2-methyl-3-((4r,5r)-1,3,4,5-tetrahydro-4-(methylamino)benz(cd)indol-5-yl)-, (2e)-
(-)-chanoclavine i
secaclavine
6,7-secoergoline-8-methanol, 8,9-didehydro-6-methyl-, (e)-
secaclavin
chanoclavine [mi]
chanoclavine i
(e)-2-methyl-3-[(4r,5r)-4-(methylamino)-1,3,4,5-tetrahydrobenzo[cd]indol-5-yl]prop-2-en-1-ol
chanoclavine-i; isochanoclavin
DTXSID50893242
Q15410883
(r,r)-chanoclavine

Research Excerpts

Actions

ExcerptReferenceRelevance
"Chanoclavine was found to inhibit the efflux pumps which seem to be ATPase-dependent."( Synergy of clavine alkaloid 'chanoclavine' with tetracycline against multi-drug-resistant E. coli.
Darokar, MP; Dwivedi, GR; Gupta, MK; Khan, F; Maurya, A; Singh, M; Singh, V; Srivastava, SK; Yadav, DK, 2019
)
1.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (5)

ClassDescription
ergot alkaloid
benzoindole
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
primary alcoholA primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.
organic heterotricyclic compoundAn organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (26.09)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's15 (65.22)24.3611
2020's2 (8.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.94 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]